imatinib mesylate has been researched along with Anomalous Ventricular Excitation Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alimena, G; Breccia, M; Cannella, L; Federico, V; Loglisci, G; Santopietro, M | 1 |
1 other study(ies) available for imatinib mesylate and Anomalous Ventricular Excitation Syndrome
| Article | Year |
|---|---|
Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months.
Topics: Adult; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Failure; Treatment Outcome; Wolff-Parkinson-White Syndrome | 2010 |